Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas at European Hemato
9/6 09:01
Media Release COPENHAGEN, Denmark ; June 9 , 202 3 , at 9:00am CEST R esults from phase 1/2 EPCORE™ NHL-2 trial investigating e pcoritamab in combination with rituximab-lenalidomide (R2) show ed a 98 percent overall response rate (ORR), 87 percent complete metabolic response (CMR) in patients with...